Alkem Laboratories
Market cap ₹60,829 Cr
- P/E
- 28.21
- Day range
- ₹5,051.00 – ₹5,128.00
- 52-week range
- ₹5,051.00 – ₹5,933.50
- Volume
- 2.39 L
- Open
- ₹5,122.00
- Prev close
- ₹5,138.00
Price history
Price & delivery on the exchange
NSE bhavcopy to 11 Sept 2026 · delivery 78.4% today vs 52.0% average · BSE close ₹5,089.5
- Delivery
- NSE close
- BSE close
High delivery with a rising price suggests buyers holding rather than trading the move.
Futures & options
NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026
- Near-month future
- ₹5,118.5
- Change
- -0.41%
- Basis over spot
- +₹31.00
- Futures OI (shares)
- 16.1 L
- OI change
- +1.85%
- Put-call ratio
- 0.67
- Max pain
- ₹5,200
- Resistance (call OI)
- ₹5,200
- Support (put OI)
- ₹5,200
- Lot size
- 125
Open interest by strike
Calls open above (resistance) and puts below (support), in shares
- Call OI
- Put OI
Futures open interest and price
Near-month future, day by day since collection began
The daily history builds from each close.
Key metrics
- P/E (TTM)
- 30.9
- EPS (TTM)
- ₹180.45
- Price / Book
- 4.45
- ROE (FY26)
- 18.2%
- ROCE (latest year)
- 21%
- Dividend yield
- 1.03%
- Net margin (TTM)
- 14.6%
- Current ratio
- 2.55
- Debt / Equity
- 0.06
- Revenue growth (5y)
- 10.7%
- EPS growth (5y)
- 7.8%
Moving averages (NSE)
| 5-day | 10-day | 20-day | 50-day | 100-day | 300-day |
|---|---|---|---|---|---|
| ₹5,203.3Price below | ₹5,262.45Price below | ₹5,333.58Price below | ₹5,512.14Price below | ₹5,469.09Price below | ₹5,523.62Price below |
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
Bars in ₹ crore (a loss shows red); line is operating margin
- Revenue
- Net profit
- Operating margin
Who owns the company
Shareholding as of Jun 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); line is debt-to-equity
- Equity
- Debt
- Debt / equity
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating Profit | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other Income | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net Profit | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.58 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.78 | ₹43.49 |
From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.
Strengths, risks & growth
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Strengths
- Company has been maintaining a healthy dividend payout of 26.3%
Risks
- Promoter holding has decreased over last quarter: -1.50%
- The company has delivered a poor sales growth of 10.7% over past five years.
Compounded Sales Growth
- 10 Years
- +12%
- 5 Years
- +11%
- 3 Years
- +8%
- TTM
- +13%
Compounded Profit Growth
- 10 Years
- +12%
- 5 Years
- +9%
- 3 Years
- +32%
- TTM
- 0%
Stock Price CAGR
- 10 Years
- +12%
- 5 Years
- +6%
- 3 Years
- +12%
- 1 Year
- -6%
Return on Equity
- 10 Years
- +18%
- 5 Years
- +18%
- 3 Years
- +19%
- Last Year
- +19%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 51.20% | 51.20% | 51.20% | 49.70% | -1.50 pp |
| FII | 9.47% | 9.97% | 10.15% | 10.42% | +0.27 pp |
| DII | 21.93% | 21.54% | 21.39% | 22.64% | +1.25 pp |
| Public | 17.39% | 17.30% | 17.25% | 17.25% | 0.00 pp |
Filed with NSE for Jun 2026: promoters 49.70%, public 50.30% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 16.71% (+1.14 pp)- Promoters49.7%
- Foreign institutions10.4%
- Mutual funds16.7%
- Insurance4.1%
- Other domestic institutions1.8%
- Retail1.1%
- Others16.1%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Mid Cap Fund | 2.71% | 1.61% | -0.13 pp |
| ICICI Pru Multi Asset Allocation Fund | 1.28% | 0.94% | -0.07 pp |
| SBI Large & Midcap Fund | 1.22% | 1.86% | -0.15 pp |
| Nippon India Growth Mid Cap Fund | 1.02% | 1.25% | -0.06 pp |
| Axis Midcap Fund | 0.74% | 1.34% | +0.49 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Corporate actions
- dividend₹10.00
Dividend - Rs 10 Per Share
7 Aug 2026ex-date - dividend₹43.00
Interim Dividend - Rs 43 Per Share
20 Feb 2026ex-date - dividend₹8.00
Dividend - Rs 8 Per Share
8 Aug 2025ex-date - dividend₹37.00
Interim Dividend - Rs 37 Per Share
14 Feb 2025ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
9 Aug 2024ex-date - dividend₹35.00
Interim Dividend - Rs 35 Per Share
16 Feb 2024ex-date - dividend₹10.00
Dividend - Rs 10 Per Share
10 Aug 2023ex-date - dividend₹15.00
Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share
17 Feb 2023ex-date - dividend₹4.00
Dividend - Rs 4 Per Share
8 Aug 2022ex-date - dividend₹30.00
Interim Dividend - Rs 30 Per Sh
10 Feb 2022ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
9 Aug 2021ex-date - dividend₹25.00
Interim Dividend - Rs 25 Per Share
11 Feb 2021ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
10 Aug 2020ex-date - dividend₹22.00
Interim Dividend - Rs 22 Per Share
13 Feb 2020ex-date - dividend₹8.00
Annual General Meeting/Dividend - Rs 8 Per Share
19 Aug 2019ex-date - dividend₹8.00
Interim Dividend - Rs 8 Per Share
15 Feb 2019ex-date - dividend₹7.00
Annual General Meeting/Dividend- Rs 7 Per Share
23 Aug 2018ex-date - dividend₹6.00
Interim Dividend - Rs 6 Per Share (Purpose Revised)
16 Feb 2018ex-date - dividend₹9.00
Annual General Meeting/ Dividend -Rs 9/- Per Share
31 Aug 2017ex-date - dividend₹6.00
Interim Dividend Rs 6/- Per Share
23 Nov 2016ex-date
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 25,000 | ₹9.0 Cr | 29 Mar 2022 |
Mritunjay Kumar Singh Director · Market Purchase | Buy | 3,357 | ₹1.1 Cr | 8 Mar 2022 |
Mritunjay Kumar Singh Director · Market Purchase | Buy | 1,643 | ₹51.9 L | 8 Mar 2022 |
Dhananjay and Madhurima Singh Trust Promoters · Market Purchase | Buy | 1,050 | ₹34.4 L | 25 Feb 2022 |
Dhananjay and Madhurima Singh Trust Promoters · Market Purchase | Buy | 2,000 | ₹65.9 L | 23 Feb 2022 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 2,000 | ₹69.8 L | 30 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 2,000 | ₹68.7 L | 27 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 5,000 | ₹1.7 Cr | 23 Dec 2021 |
Jayanti Sinha Promoter Group · Gift | Sell | 20,00,000 | ₹0 | 2 Dec 2021 |
Deepak Kumar Singh Employees/Designated Employees · Market Sale | Sell | 5,000 | ₹1.8 Cr | 18 Nov 2021 |
Balmiki Prasad Singh Director · Off Market | Buy | 50,266 | ₹0 | 5 Oct 2021 |
Satish Kumar Singh Promoters · Off Market | Buy | 50,267 | ₹0 | 5 Oct 2021 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Company announcements
Alkem Laboratories Limited launches Renocia ExoTM, India's first patented Ginsenoside Exosome - based hair growth serum
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.
Please find attached herewith Outcome of the 52nd Annual General Meeting of the Company and disclosure of voting results thereat.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer's Report on e-voting.
Please find attached herewith intimation for a copy of newspaper publication
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the ' Q1FY27 Earnings Conference Call' is available ....
The Financials Results of the Company for the quarter ended 30th June, 2026 having been communicated to the Stock Exchanges today ie 14th Aug the trading window shall open on 17th Aug, 2026.
Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the Company
Pl find attached herewith intimation under Reg 30
Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 2026
Please find enclosed herewith the outcome of Board meeting dated 14th Aug, 2026. The meeting of the Board of Directors of the Company commenced at 11 am and concluded at 13.40 pm. Kindly take the same
Please find attached herewith intimation about update on US FDA inspection at Company's Manufacturing Facility Located at Amaliya, Daman.
Filed with BSE (scrip 539523); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Settlement order
Settlement Order in respect of IIFL Securities Limited in the matter of Alkem Laboratories Ltd.
25 Feb 2022Read on SEBI - Order
Order in the matter of Alkem Laboratories Limited.
10 Mar 2017Read on SEBI
Documents
Annual reports
Earnings calls
- Aug 2026Transcript
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlides
- Feb 2026Slides
- Feb 2026TranscriptSlides
- Feb 2026Slides
Credit ratings
- Rating update · 8 Jul from crisil
- Rating update · 24 Feb from crisil
- Rating update · 6 Feb from fitch
- Rating update · 5 Jan from care
- Rating update · 15 Sep 2025 from crisil
- Rating update · 7 Feb 2025 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 7 Feb 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.
